441 related articles for article (PubMed ID: 16012715)
21. [Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma].
Tokuyama T; Yoneda T; Hamada K; Yoshikawa M; Fu A; Tomoda K; Nakaya M; Narita N; Tamura M; Kitamura K
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Jan; 33(1):39-43. PubMed ID: 7699966
[TBL] [Abstract][Full Text] [Related]
22. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
[TBL] [Abstract][Full Text] [Related]
23. Cytokeratin 19 fragment/carcinoembryonic antigen ratio in pleural effusion is a useful marker for detecting malignant pleural mesothelioma.
Suzuki H; Hirashima T; Kobayashi M; Sasada S; Okamoto N; Uehara N; Tamiya M; Matsuura Y; Morishita N; Kawase I
Anticancer Res; 2010 Oct; 30(10):4343-6. PubMed ID: 21036761
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma.
Filho AL; Baltazar F; Bedrossian C; Michael C; Schmitt FC
Diagn Cytopathol; 2007 Dec; 35(12):786-91. PubMed ID: 18008346
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological analysis of lung cancer resembling malignant pleural mesothelioma.
Kobashi Y; Matsushima T; Irei T
Respirology; 2005 Nov; 10(5):660-5. PubMed ID: 16268922
[TBL] [Abstract][Full Text] [Related]
26. The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
Rakha EA; Patil S; Abdulla K; Abdulkader M; Chaudry Z; Soomro IN
Diagn Cytopathol; 2010 Dec; 38(12):874-9. PubMed ID: 20049969
[TBL] [Abstract][Full Text] [Related]
27. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in differentiating malignant from benign pleural effusion.
Dong J; Sun G; Zhu H
Tumour Biol; 2016 Mar; 37(3):3257-64. PubMed ID: 26438059
[TBL] [Abstract][Full Text] [Related]
29. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma.
Edwards JG; Faux SP; Plummer SM; Abrams KR; Walker RA; Waller DA; O'Byrne KJ
Clin Cancer Res; 2002 Jun; 8(6):1857-62. PubMed ID: 12060628
[TBL] [Abstract][Full Text] [Related]
30. Expression of GATA-6 transcription factor in pleural malignant mesothelioma and metastatic pulmonary adenocarcinoma.
Lindholm PM; Soini Y; Myllärniemi M; Knuutila S; Heikinheimo M; Kinnula VL; Salmenkivi K
J Clin Pathol; 2009 Apr; 62(4):339-44. PubMed ID: 19060016
[TBL] [Abstract][Full Text] [Related]
31. Malignant mesothelioma with prominent adenomatoid features: a clinicopathologic and immunohistochemical study of 10 cases.
Weissferdt A; Kalhor N; Suster S
Ann Diagn Pathol; 2011 Feb; 15(1):25-9. PubMed ID: 21106421
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of pleural fluid pH in malignant epithelial mesothelioma after talc poudrage.
Aelony Y; Yao JF; King RR
Respiration; 2006; 73(3):334-9. PubMed ID: 16679752
[TBL] [Abstract][Full Text] [Related]
33. Invasive potency related to RCAS1 expression in uterine cervical cancer.
Sonoda K; Miyamoto S; Hirakawa T; Yagi H; Yotsumoto F; Nakashima M; Watanabe T; Nakano H
Gynecol Oncol; 2005 Oct; 99(1):189-98. PubMed ID: 16112176
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations.
Rena O; Boldorini LR; Gaudino E; Casadio C
J Surg Oncol; 2011 Nov; 104(6):701-5. PubMed ID: 21437912
[TBL] [Abstract][Full Text] [Related]
35. Clinico-pathological significance of RCAS1 expression in gliomas: a potential mechanism of tumor immune escape.
Nakabayashi H; Nakashima M; Hara M; Toyonaga S; Yamada SM; Park KC; Shimizu K
Cancer Lett; 2007 Feb; 246(1-2):182-9. PubMed ID: 16595162
[TBL] [Abstract][Full Text] [Related]
36. Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma.
Yan TD; Boyer M; Tin MM; Sim J; Kennedy C; McLean J; Bannon PG; McCaughan BC
Ann Thorac Surg; 2009 May; 87(5):1552-6. PubMed ID: 19379903
[TBL] [Abstract][Full Text] [Related]
37. Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma.
Matsuzaki Y; Tomita M; Shimizu T; Hara M; Ayabe T; Onitsuka T
Ann Thorac Cardiovasc Surg; 2008 Jun; 14(3):161-5. PubMed ID: 18577894
[TBL] [Abstract][Full Text] [Related]
38. Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy.
Nakas A; Trousse DS; Martin-Ucar AE; Waller DA
Eur J Cardiothorac Surg; 2008 Oct; 34(4):886-91. PubMed ID: 18656373
[TBL] [Abstract][Full Text] [Related]
39. A clinical and immunohistochemical study on gastrointestinal mesenchymal tumor (GIMT): RCAS1 as a predictor for recurrence of GIMT.
Naito A; Narikiyo M; Yamada Y; Ueno M; Kamada K; Hachisuka T; Yoriki R; Mizuno T; Nakajima Y
Oncol Rep; 2005 Nov; 14(5):1127-32. PubMed ID: 16211275
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors for 100 patients with malignant pleural mesothelioma.
Gonlugur U; Gonlugur TE
Arch Environ Occup Health; 2010; 65(2):65-9. PubMed ID: 20439224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
